The Emerging Genetic Basis and Its Clinical Implication in Pancreatic Cancer
The Emerging Genetic Basis and Its Clinical Implication in Pancreatic Cancer
复制标题
DOI：
10.1159/000435764
复制
发表时间：
2015-07
影响因子：
1.6
通讯作者：
Fei Chen;Yang Guo;Liangjing Wang
中科院分区：
文献类型：
--
作者：
Fei Chen;Yang Guo;Liangjing Wang
背景资料：胰腺癌是最具破坏性的疾病之一，没有早期发现，有效的筛选生物标志物和治疗性治疗。在过去的几十年里，遗传学研究表明，各种基因与这种恶性肿瘤有关。总结：基因改变参与了胰腺癌的发生、发展和侵袭，这可能为早期筛查、诊断和未来干预提供有希望的靶点。在这里，我们将回顾胰腺癌的遗传变化，并分析它们与几种常见前体和家族综合征的相关性。关键信息：胰腺癌或其前体的遗传分析可能有助于我们在未来将患者特征化为亚型个体，并对个体化治疗具有重要意义。实际影响：目前，胰腺癌被认为是一种具有广泛遗传改变的疾病，包括种系和体细胞突变。KRAS、p16 CDKN2A、TP53和SMAD 4等基因改变与胰腺癌的不同组织学类型的前体细胞和与胰腺癌高度相关的家族综合征特异性相关。此外，遗传变化还预测药物敏感性和暗示新的治疗靶点。
Background: Pancreatic cancer is one of the most devastating diseases without early detection, effective screening biomarkers and therapeutic treatments. In the past decades, genetic studies have indicated various genes related to this malignancy. Summary: Genetic alterations have been involved in the initiation, progression and invasion of pancreatic cancer, which might indicate promising targets for early screening, diagnosis and future intervention. Here we will review genetic changes in pancreatic cancer and analyze their correlations with several common precursors and familial syndromes. Key Message: Genetic analysis for pancreatic cancer or its precursors might help us to characterize patients into subtype individuals in the future and have significant implications for individualized treatments. Practical Implications: At present, pancreatic cancer is regarded as a disease with a wide range of genetic alterations, including germline and somatic mutations. Some genetic alterations such as KRAS, p16CDKN2A, TP53 and SMAD4 were specifically correlated with different types of histological precursors of pancreatic cancer and some familial syndromes highly related to pancreatic cancer. Moreover, genetic changes also predict drug sensitivity and implicate novel therapeutic targets.